The regulation of cellular functions by the p53 protein: Cellular senescence

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 2, 2017, Pages

  Tonnessen Murray, Crystal A ^a   Lozano, Guillermina ^b   Jackson, James G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL AGING; CELL CYCLE PROGRESSION; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; DNA DAMAGE; DNA DAMAGE RESPONSE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; REGULATORY MECHANISM; SENESCENCE; SIGNAL TRANSDUCTION; TRANSFORMED CELL; CELL DIVISION; GENETICS; NEOPLASM; PHYSIOLOGY;

CELL DIVISION; CELLULAR SENESCENCE; DNA DAMAGE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85011593467     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026112     Document Type: Article

References (122)

1. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, Pillai MR. 2011. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem 286: 37813–37829.
2. Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, et al. 2008. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133: 1006–1018.
3. Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB. 2012. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: Implications for targeting mTOR during malignancy. Oncogene 31: 1949–1962.
4. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. 1995. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci 92: 8348–8352.
5. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. 1998. Enhanced phosphorylation of p53 by ATMin response to DNA damage. Science 281: 1674–1677.
6. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. 2006. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci 103: 19842–19847.
7. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al. 2006. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633–637.
8. Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstadter F, Hartmann A. 2003. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 56: 286–292.
9. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. 2003. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J 22: 4212–4222.
10. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. 2008. CXCL5 promotes prostate cancer progression. Neoplasia 10: 244–254.
11. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H. 2002. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360: 852–854.
12. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, et al. 2007. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin–cyclophosphamide regimen. PLoS Med 4: e90.
13. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352.
14. Bond J, Haughton M, Blaydes J, Gire V, Wynford-Thomas D, Wyllie F. 1996. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene 13: 2097–2104.
15. Brown JP, Wei W, Sedivy JM. 1997. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277: 831–834.
16. Cahu J, Bustany S, Sola B. 2012. Senescence-associated secretory phenotype favors the emergence of cancer stemlike cells. Cell Death Dis 3: e446.
17. Campisi J. 1997. The biology of replicative senescence. Eur J Cancer 33: 703–709.
18. Campisi J. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120: 513–522.
19. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, et al. 2012. SASP mediates chemoresistance and tumor-initiating activity of mesotheliomacells. Oncogene 31: 3148–3163.
20. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677–1679.
21. Cao L, Li W, Kim S, Brodie SG, Deng CX. 2003. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17: 201–213.
22. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB. 1999. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59: 3761–3767.
23. Chen X, Zhang W, Gao YF, Su XQ, Zhai ZH. 2002. Senescence-like changes induced by expression of p21Waf1/Cip1 in NIH3T3 cell line. Cell Res 12: 229–233.
24. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725–730.
25. Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, Ji ZY, Lu PH. 2012. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: A metaanalysis. PLoS ONE 7: e39655.
26. Chin L, Artandi SE, Shen Q, Tam A, Lee S-L, Gottlieb GJ, Greider CW, DePinho RA. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97: 527–538.
27. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. 2014. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer cell 25: 152–165.
28. Choudhury AR, Ju Z, Djojosubroto MW, Schienke A, Lechel A, Schaetzlein S, Jiang H, Stepczynska A, Wang C, Buer J, et al. 2007. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 39: 99–105.
29. Collado M, Serrano M. 2010. Senescence in tumours: Evidence frommice and humans. Nat Rev Cancer 10: 51–57.
30. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, et al. 2005. Tumour biology: Senescence in premalignant tumours. Nature 436: 642.
31. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. 2008. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853–2868.
32. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, Chang S. 2007. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8: 497–503.
33. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921–1929.
34. Courtois-Cox S, GentherWilliams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. 2006. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10: 459–472.
35. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. 2003. A DNA damage checkpoint response in telomereinitiated senescence. Nature 426: 194–198.
36. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379–384.
37. Dhawan P, Richmond A. 2002. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 72: 9–18.
38. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. 2009. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294–303.
39. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. ProcNatl Acad Sci 92: 9363–9367.
40. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993.WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
41. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE. 2002. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 277: 35509–35515.
42. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, et al. 2012. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132: 1049–1062.
43. Ewald J, Desotelle J, Almassi N, Jarrard D. 2008. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 98: 1244–1249.
44. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. 2010. Therapy-induced senescence in cancer. J Natl Cancer Inst 102: 1536–1546.
45. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. 1999. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18: 2789–2797.
46. Feldser DM, Greider CW. 2007. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11: 461–469.
47. Ferreira R, Naguibneva I, Pritchard LL, Ait-Si-Ali S, Harel-Bellan A. 2001. The Rb/chromatin connection and epigenetic control: Opinion. Oncogene 20: 3128–3133.
48. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. 2009. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27: 4798–4808.
49. Gorgoulis VG, Halazonetis TD. 2010. Oncogene-induced senescence: The bright and dark side of the response. Curr Opin Cell Biol 22: 816–827.
50. Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345: 458–460.
51. Hayflick L. 1965. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614–636.
52. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. 2004. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a. Mol Cell 14: 501–513.
53. Hornsby PJ. 2002. Cellular senescence and tissue aging in vivo. J Gerontol A Biol Sci Med Sci 57: B251–B256.
54. Ide T, Tsuji Y, Ishibashi S, Mitsui Y. 1983. Reinitiation of host DNA synthesis in senescent human diploid cells by infection with simian virus 40. Exp Cell Res 143: 343–349.
55. Ide T, Tsuji Y, Nakashima T, Ishibashi S. 1984. Progress of aging in human diploid cells transformed with a tsA mutant of simian virus 40. Exp Cell Res 150: 321–328.
56. Itahana K, Dimri G, Campisi J. 2001. Regulation of cellular senescence by p53. Eur J Biochem 268: 2784–2791.
57. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280–10288.
58. Jackson JG, Pereira-Smith OM. 2006a. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res 66: 8356–8360.
59. Jackson JG, Pereira-Smith OM. 2006b. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 26: 2501–2510.
60. Jackson JG, Post SM, Lozano G. 2011. Regulation of tissueand stimulus-specific cell fate decisions by p53 in vivo. J Pathol 223: 127–136.
61. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al. 2012. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21: 793–806.
62. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. 2011. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479: 547–551.
63. Karnoub AE, Weinberg RA. 2006. Chemokine networks and breast cancer metastasis. Breast Dis 26: 75–85.
64. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, et al. 1998. ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat Genet 20: 398–400.
65. Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. 2007. Activation of p53-dependent growth suppression in human cells by mutations in PTENor PIK3CA. MolCell Biol 27: 662–677.
66. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc Natl Acad Sci 98: 12072–12077.
67. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. 2008. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133: 1019–1031.
68. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. 2000. Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113: 3613–3622.
69. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES. 2006. Senescenceassociated β-galactosidase is lysosomal β-galactosidase. Aging Cell 5: 187–195.
70. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12: 3008–3019.
71. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. 2004. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36: 63–68.
72. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847–849.
73. Ma Y, Prigent SA, Born TL, Monell CR, Feramisco JR, Bertolaet BL. 1999. Microinjection of anti-p21 antibodies induces senescent Hs68 human fibroblasts to synthesize DNA but not to divide. Cancer Res 59: 5341–5348.
74. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, et al. 2012. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122: 1541–1552.
75. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, et al. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev 15: 1067–1077.
76. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.
77. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF. 2007. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2: e441.
78. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, et al. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci 107: 246–251.
79. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703–716.
80. Neufeld DS, Ripley S, Henderson A, Ozer HL. 1987. Immortalization of human fibroblasts transformed by origindefective simian virus 40. Mol Cell Biol 7: 2794–2802.
81. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90–98.
82. Novakova Z, Hubackova S, Kosar M, Janderova-Rossmeislova L, Dobrovolna J, Vasicova P, Vancurova M, Horejsi Z, Hozak P, Bartek J, et al. 2010. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 29: 273–284.
83. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, et al. 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157–1167.
84. Ota S, Zhou ZQ, Link JM, Hurlin PJ. 2009. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet 18: 2609–2621.
85. Perez-Mancera PA, Young AR, Narita M. 2014. Inside and out: The activities of senescence in cancer. Nat Rev Cancer 14: 547–558.
86. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. 2010. p53-dependent senescence delays Em-myc-induced B-cell lymphomagenesis. Oncogene 29: 1260–1269.
87. Radna RL, Caton Y, Jha KK, Kaplan P, Li G, Traganos F, Ozer HL. 1989. Growth of immortal simian virus 40 tsA-transformed human fibroblasts is temperature dependent. Mol Cell Biol 9: 3093–3096.
88. Rodier F, Campisi J, Bhaumik D. 2007. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 35: 7475–7484.
89. Roninson IB. 2002. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 5: 204–208.
90. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, DePinho RA. 1999. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701–712.
91. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. 2007. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 493–505.
92. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335–346.
93. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602.
94. Shai A, Dankort D, Juan J, Green S, McMahon M. 2015. TP53 silencing bypasses growth arrest of BRAFV600E-induced lung tumor cells in a two-switch model of lung tumorigenesis. Cancer Res 75: 3167–3180.
95. Sharpless NE, Sherr CJ. 2015. Forging a signature of in vivo senescence. Nat Rev Cancer 15: 397–408.
96. Sherr CJ. 2000. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 60: 3689–3695.
97. Sherr CJ, McCormick F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2: 103–112.
98. Sidi R, Pasello G, Opitz I, Soltermann A, Tutic M, Rehrauer H, Weder W, Stahel RA, Felley-Bosco E. 2011. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis. Eur J Cancer 47: 326–332.
99. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Borresen-Dale AL, et al. 2014. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20: 3569–3580.
100. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. 2007. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25: 4414–4422.
101. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703–711.
102. Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. 2000. Autocrine growth effect of IL-8 and GROa on a human pancreatic cancer cell line, Capan-1. Pancreas 21: 52–56.
103. TCGA-Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
104. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876–1883.
105. Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, et al. 2005. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res 65: 840–849.
106. Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR, Sanchez LM, Zhou Z, Rodriguez FJ, Stewart CL, Vega JA, et al. 2005. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 437: 564–568.
107. Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, et al. 2009. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 124: 991–997.
108. Vaziri H, West MD, Allsopp RC, Davison TS, Wu YS, Arrowsmith CH, Poirier GG, Benchimol S. 1997. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 16: 6018–6033.
109. Velarde MC, Demaria M, Campisi J. 2013. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 38: 17–27.
110. von Zglinicki T, Saretzki G, Ladhoff J, d’Adda di Fagagna F, Jackson SP. 2005. Human cell senescence as a DNA damage response. Mech Ageing Dev 126: 111–117.
111. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2008. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363–374.
112. Wajapeyee N, Wang SZ, Serra RW, Solomon PD, Nagarajan A, Zhu X, Green MR. 2010. Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins. Blood 115: 5057–5060.
113. Wang Y, Xu Y, Chen J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. 2015. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/ cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer. Int J Cancer 138: 489–496.
114. Wei W, Herbig U, Wei S, Dutriaux A, Sedivy JM. 2003. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBORep 4: 1061–1065.
115. Weller M. 1998. Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res 292: 435–445.
116. Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, Alt FW, DePinho RA. 2003. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 421: 643–648.
117. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. 2013. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130: 565–569.
118. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
119. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656–660.
120. Yang X, Lu P, Fujii C, Nakamoto Y, Gao JL, Kaneko S, Murphy PM, Mukaida N. 2006. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer 118: 1869–1876.
121. Zenz T, Benner A, Dohner H, Stilgenbauer S. 2008. Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle 7: 3810–3814.
122. Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12: 2997–3007.